Market Overview

UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products

Related BLUE
Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year
10 Biotech Stories You Might've Missed This Week
Winners Circle 2014 Top Hedge Fund Managers: Healthcare Funds, Nine Of Top Ten Spots (Seeking Alpha)

In a report published on Monday, J.P. Morgan analyst Cory Kasimov initiated coverage on bluebird bio (NASDAQ: BLUE) with an Overweight rating and a $44 price target.

In the report, J.P. Morgan stated, "Catchy titles aside, bluebird bio is anything but “Old School.” Quite the contrary. In our view, BLUE – with its gene therapy platform – is one of the more potentially transformative and disruptive companies we've come across in some time. Importantly, however, this appears to be more than just a “big idea.” bluebird has already established promising proof-of-concept for its two lead products and is going after orphan indications with a very high unmet medical need that could bolster the ultimate probability of success."

bluebird bio closed on Friday at $30.65.

Latest Ratings for BLUE

Dec 2014Roth CapitalMaintainsBuy
Dec 2014WedbushReiteratesOutperform
Sep 2014Roth CapitalInitiates Coverage onBuy

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Cory Kasimov J.P.MorganAnalyst Color Initiation Analyst Ratings


Related Articles (BLUE)

Around the Web, We're Loving...

Get Benzinga's Newsletters